Document Detail

Cholesterol and cardiac arrhythmias.
MedLine Citation:
PMID:  20602558     Owner:  NLM     Status:  MEDLINE    
Cardiac arrhythmias are a leading cause of morbidity and mortality in the Western world. Ventricular arrhythmias are reportedly responsible for the majority of sudden cardiac deaths and atrial fibrillation is responsible for 15% of all strokes in the USA. Recent evidence suggests a role for cholesterol in the development of these arrhythmias. In addition to its association with atherosclerotic plaques, high cholesterol has been shown to cause changes in membrane properties, including the function of hormone receptors, ion channels and pumps. These effects are mediated through direct interactions between cholesterol and the membrane proteins, through changes in membrane fluidity and/or an association with lipid rafts. Cholesterol-lowering therapy, therefore, may prove an effective method for the treatment of cardiac arrhythmias. Statins, a class of cholesterol-lowering drugs, have been frequently shown to protect against ventricular arrhythmias and atrial fibrillation. Some of this protection may stem from their cholesterol-lowering activities.
Charitha L Goonasekara; Elise Balse; Stephan Hatem; David F Steele; David Fedida
Related Documents :
15882678 - Failure to achieve recommended ldl cholesterol levels by suboptimal statin therapy rela...
15156218 - Lipid profile during the first 24 hours after myocardial infarction has significant pro...
10503268 - Serum lipoprotein(a) profiles in a singaporean population.
18041998 - The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigatio...
7362708 - Pulsed doppler echocardiography for diagnosis of ventricular septal defects.
8965108 - The size of territorial brain infarction on ct relates to the degree of internal caroti...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  8     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-06     Completed Date:  2010-10-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  965-79     Citation Subset:  IM    
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticholesteremic Agents / therapeutic use
Arrhythmias, Cardiac / drug therapy,  etiology*,  prevention & control
Atrial Fibrillation / prevention & control
Cell Membrane / physiology
Cholesterol / biosynthesis,  blood*,  metabolism
Heart Ventricles
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Ion Channels / metabolism
Ion Pumps / metabolism
Membrane Fluidity
Membrane Microdomains / physiology
Myocardium / metabolism
Protein Transport
Receptors, Cell Surface / metabolism
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Ion Channels; 0/Ion Pumps; 0/Receptors, Cell Surface; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cardiac resynchronization therapy in patients with minimally symptomatic heart failure.
Next Document:  Obstructive sleep apnea: novel trigger and potential therapeutic target for cardiac arrhythmias.